<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="utf-8">

  <title>NICE Formulary - IBUPROFEN</title>

  <meta name="X-UA-Compatible" content="IE=edge,chrome=1">
  <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
  <meta name="description" content="">
  <meta name="author" content="NICE - The National Institute of Health and Care Excellence">

  <!--[if lt IE 9]>
  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/html5shiv.js"></script>
  <![endif]-->

  <!-- Le styles -->
  <link rel="stylesheet" href="http://mattonfoot.github.io/NICE.UI/styles/ui.css">

  <!-- Fav and touch icons -->
  <link rel="shortcut icon" href="http://cdn.nice.org.uk/V3/Content/nice/favicon.ico">
  <link rel="apple-touch-icon-precomposed" href="http://cdn.nice.org.uk/V3/Content/nice/favicon-152.png">
  <meta name="msapplication-TileColor" content="#fafafb">
  <meta name="msapplication-TileImage" content="http://cdn.nice.org.uk/V3/Content/nice/favicon-144.png">

  <style>
  .tab-content {
    overflow: auto;
  }
  .tab-content > .tab-pane {
    display: none;
  }
  .tab-content > .active {
    display: block;
  }

  header .nav {
    list-style: decimal inside none;
  }
  header .nav > li {
    display: list-item;
  }
  header .nav > li > a {
    display: block;
    margin: 0;
    padding: 0;
    text-decoration: none;
    color: #01769d;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus,
  header .nav > li.active > a,
  header .nav > li.active > a:hover,
  header .nav > li.active > a:focus {
    outline: 0;
    color: #08455b;
    background: transparent;
    text-decoration: none;
  }
  header .nav > li > a:hover,
  header .nav > li > a:focus {
    text-decoration: underline;
  }

  [outputclass="title"],
  .title {
    font-size: 19px;
    font-size: 1.9rem;
    line-height: 24px;
    line-height: 2.4rem;
  }

  h3, h4, h5, h6, .title, [outputclass="title"] {
    margin-bottom: 0;
  }

  h1+p, h2+p, h3+p, h4+p, h5+p, h6+p, .title+p, [outputclass="title"]+p {
    margin-top: 0;
  }

  .doses {
    padding-left: 0;
    list-style: none;
  }
  .doses .dose {
    padding-left: 24px;
    padding-left: 2.4rem;
    margin-bottom: 6px;
    margin-bottom: .6rem;
  }
  .doses .adult {
    border-left: 7px solid #346e7f;
  }
  .doses .child {
    border-left: 7px solid #82176F;
  }

  /* DITA symbols */

  ph {
    color: #006;
  }

  tm::before {
    font-size: .8em;
    margin-left: -.2em;
    vertical-align: top;
  }
  tm[tmtype="reg"]::before {
    content: "\00ae";
  }
  tm[tmtype="copy"]::before {
    content: "\00a9";
  }
  tm[tmtype="trade"]::before {
    content: "\2122";
  }

  </style>
</head>

<body id="" class="">
  <header>
    <div class="container">
      <ul class="breadcrumb">
        <li><a href="../">Home</a> <span class="divider glyph-chevron-right"></span></li>
        <li class="active"><a href="../drug/">Drugs</a></li>
      </ul>

      <h1>IBUPROFEN</h1>


      <nav>
        <ul class="nav nav-list">

          <li class="active"><a href="#indicationsAndDoses" data-toggle="tab">Indications and doses</a></li>
          <li><a href="#pregnancy" data-toggle="tab">Pregnancy</a></li>
          <li><a href="#hepaticImpairment" data-toggle="tab">Hepatic impairment</a></li>
          <li><a href="#renalImpairment" data-toggle="tab">Renal impairment</a></li>
          <li><a href="#contraindications" data-toggle="tab">Contra indications</a></li>
          <li><a href="#sideEffects" data-toggle="tab">Side effects</a></li>
          <li><a href="#directionsForAdministration" data-toggle="tab">Administration</a></li>
          <li><a href="#patientAndCarerAdvice" data-toggle="tab">Patient and carer advice</a></li>
          <li><a href="#cautions" data-toggle="tab">Cautions</a></li>
          <li><a href="#conceptionAndContraception" data-toggle="tab">conception and contraception</a></li>
          <li><a href="#monitoringRequirements" data-toggle="tab">Monitoring requirements</a></li>
          <li><a href="#unlicensedUse" data-toggle="tab">Unlicensed use</a></li>
          <li><a href="#prescribingAndDispensingInformation" data-toggle="tab">Prescribing and dispensing</a></li>
          <li><a href="#professionSpecificInformation" data-toggle="tab">Profession specific information</a></li>
          <li><a href="#exceptionsToLegalCategory" data-toggle="tab">Exceptions to legal category</a></li>
          <li><a href="#allergyAndCrossSensitivity" data-toggle="tab">Allergy and cross sensitivity</a></li>
          <li><a href="#medicinalForms" data-toggle="tab">Medicinal forms</a></li>
        </ul>
      </nav>

      <br/>
    </div>
  </header>

  <div class="container">
    <div class="tab-content">

      <section class="tab-pane active" id="indicationsAndDoses">
        <h2>Indications and doses</h2>

        <section class="indicationAndDoseGroups">
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Pain and inflammation in rheumatic disease and other musculoskeletal disorders</span>,
                <span class="indication">Mild to moderate pain including dysmenorrhoea</span>,
                <span class="indication">Postoperative analgesia</span>,
                <span class="indication">Migraine</span>,
                <span class="indication">Dental pain</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using modified-release medicines</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Initially 300&#8211;400 mg 3&#8211;4 times a day; increased if necessary up to 600 mg 4 times a day; maintenance 200&#8211;400 mg 3 times a day, may be adequate.</li>
              <li class="dose adult"><strong>For adults </strong><br/>
                1.6 g once daily, dose to be taken in the early evening, increased if necessary to 2.4 g daily in 2 divided doses, dose to be increased only in severe cases.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Mild to moderate pain</span>,
                <span class="indication">Pain and inflammation of soft-tissue injuries</span>,
                <span class="indication">Pyrexia with discomfort</span>,
            </h4>
            <p class="specificity"><span class="route">Initially by mouth using immediate-release medicines</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children 3&#8211;5 months</strong><br/>
                50 mg 3 times a day, maximum daily dose to be given in 3&#8211;4 divided doses; maximum 30 mg/kg per day.</li>
              <li class="dose child"><strong>For children 6&#8211;11 months</strong><br/>
                50 mg 3&#8211;4 times a day, maximum daily dose to be given in 3&#8211;4 divided doses; maximum 30 mg/kg per day.</li>
              <li class="dose child"><strong>For children 1&#8211;3 years</strong><br/>
                100 mg 3 times a day, maximum daily dose to be given in 3&#8211;4 divided doses; maximum 30 mg/kg per day.</li>
              <li class="dose child"><strong>For children 4&#8211;6 years</strong><br/>
                150 mg 3 times a day, maximum daily dose to be given in 3&#8211;4 divided doses; maximum 30 mg/kg per day.</li>
              <li class="dose child"><strong>For children 7&#8211;9 years</strong><br/>
                200 mg 3 times a day, maximum daily dose to be given in 3&#8211;4 divided doses; maximum 30 mg/kg per day; maximum 2.4 g per day.</li>
              <li class="dose child"><strong>For children 10&#8211;11 years</strong><br/>
                300 mg 3 times a day, maximum daily dose to be given in 3&#8211;4 divided doses; maximum 30 mg/kg per day; maximum 2.4 g per day.</li>
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                Initially 300&#8211;400 mg 3&#8211;4 times a day; (by mouth using immediate-release medicines) increased if necessary up to 600 mg 4 times a day; (by mouth) maintenance 200&#8211;400 mg 3 times a day, may be adequate.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Pain and inflammation</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using modified-release medicines</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children 12&#8211;17 years</strong><br/>
                1.6 g once daily, dose preferably taken in the early evening, increased to 2.4 g daily in 2 divided doses, dose to be increased only in severe cases.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Pain and inflammation in rheumatic disease including juvenile idiopathic arthritis</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using immediate-release medicines</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children 3 months&#8211;17 years</strong><br/>
                30&#8211;40 mg/kg daily in 3&#8211;4 divided doses; maximum 2.4 g per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Pain and inflammation in systemic juvenile idiopathic arthritis</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using immediate-release medicines</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children 3 months&#8211;17 years</strong><br/>
                Up to 60 mg/kg daily in 4&#8211;6 divided doses; maximum 2.4 g per day.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Post-immunisation pyrexia in infants (on doctor&#8217;s advice only)</span>,
            </h4>
            <p class="specificity"><span class="route">By mouth using immediate-release medicines</span></p>
            <ul class="doses">
              <li class="dose child"><strong>For children 2&#8211;3 months</strong><br/>
                50 mg for 1 dose, followed by 50 mg after 6 hours if required.</li>
            </ul>
          </section>
          <section class="indicationAndDoseGroup">
            <h4 class="indications">
                <span class="indication">Pain relief in musculoskeletal conditions</span>,
                <span class="indication">Treatment in knee or hand osteoarthritis (adjunct)</span>,
            </h4>
            <p class="specificity"><span class="route">To the skin</span></p>
            <ul class="doses">
              <li class="dose adult"><strong>For adults </strong><br/>
                Apply up to 3 times a day, ibuprofen gel 5% gel to be administered.</li>
            </ul>
          </section>
        </section>
        
        
        
        
        
      </section>



      <section class="tab-pane" id="pregnancy">
        <h2>Advice when patient is pregnant</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use</h3>
              <p>Avoid unless the potential benefit outweighs the risk.</p><p>Avoid during the third trimester (risk of closure of fetal ductus arteriosus <i>in utero</i> and possibly persistent pulmonary hypertension of the newborn); onset of labour may be delayed and duration may be increased.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use in adults</h3>
              <p>Patient packs for topical preparations carry a warning to avoid during pregnancy.</p>
            </section>
      </section>

      <section class="tab-pane" id="hepaticImpairment">
        <h2>Advice regarding hepatic impairment</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</h3>
              <p>Increased risk of gastro-intestinal bleeding and fluid retention.</p><p>Avoid in severe liver disease.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use in adults</h3>
              <p>Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention.</p><p>Avoid in severe liver disease.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>Use with caution; there is an increased risk of gastro-intestinal bleeding and fluid retention.</p><p>Avoid in severe liver disease.</p>
            </section>
      </section>

      <section class="tab-pane" id="renalImpairment">
        <h2>Advice regarding renal impairment</h2>

            <section class="doseAdjustments">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</h3>
              <p>Use lowest effective dose.</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use in adults</h3>
              <p>The lowest effective dose should be used for the shortest possible duration.</p>
            </section>
            <section class="doseAdjustments">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>The lowest effective dose should be used for the shortest possible duration.</p>
            </section>
        
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</h3>
              <p>Avoid if possible in severe impairment.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use in adults</h3>
              <p>Avoid if possible or use with caution.</p><p>Avoid in severe impairment.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>Avoid if possible or use with caution.</p><p>Avoid in severe impairment.</p>
            </section>
            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use in adults</h3>
              <p>Deterioration in renal function has also been reported after topical use.</p>
            </section>
      </section>

      <section class="tab-pane" id="contraindications">
        <h2>Contra indications</h2>

      </section>

      <section class="tab-pane" id="sideEffects">
        <h2>Known side effects</h2>

        
          <h3>Specific side effects</h3>
              <p>
                <strong>commonOrVeryCommon:</strong> bronchopulmonary dysplasia in neonates, fluid retention in neonates, haematuria in neonates, hyponatraemia in neonates, intestinal perforation in neonates, intraventricular haemorrhage in neonates, ischaemic brain injury in neonates, neutropenia in neonates, oliguria in neonates, pulmonary haemorrhage in neonates, thrombocytopenia in neonates,
              </p>
              <p>
                <strong>uncommon:</strong> gastrointestinal haemorrhage in neonates,
              </p>
              <p>
                <strong>rare:</strong> alveolitis in children, aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) in children, hepatic damage in children, interstitial fibrosis associated with NSAIDs can lead to renal failure in children, pancreatitis in children, papillary necrosis associated with NSAIDs can lead to renal failure in children, pulmonary eosinophilia in children, Stevens-Johnson syndrome in children, toxic epidermal necrolysis in children, visual disturbances in children, alveolitis in adults, aseptic meningitis (patients with connective-tissue disorders such as systemic lupus erythematosus may be especially susceptible) in adults, hepatic damage in adults, interstitial fibrosis associated with NSAIDs can lead to renal failure in adults, pancreatitis in adults, papillary necrosis associated with NSAIDs can lead to renal failure in adults, pulmonary eosinophilia in adults, Stevens-Johnson syndrome in adults, toxic epidermal necrolysis in adults, visual disturbances in adults,
              </p>
              <p>
                <strong>notKnown:</strong> hypoxaemia in neonates, angioedema in children, blood disorders in children, bronchospasm in children, colitis (induction of or exacerbation of) in children, Crohn&#8217;s disease (induction of or exacerbation of) in children, depression in children, diarrhoea in children, dizziness in children, drowsiness in children, fluid retention (rarely precipitating congestive heart failure) in children, gastro-intestinal bleeding in children, gastro-intestinal discomfort in children, gastro-intestinal disturbances in children, gastro-intestinal ulceration in children, haematuria in children, headache in children, hearing disturbances in children, hypersensitivity reactions in children, insomnia in children, nausea in children, nervousness in children, photosensitivity in children, raised blood pressure in children, rashes in children, renal failure (especially in patients with pre-existing renal impairment) in children, tinnitus in children, vertigo in children, angioedema in adults, blood disorders in adults, bronchospasm in adults, colitis (induction of or exacerbation of) in adults, Crohn&#8217;s disease (induction of or exacerbation of) in adults, depression in adults, diarrhoea in adults, dizziness in adults, drowsiness in adults, fluid retention (rarely precipitating congestive heart failure) in adults, gastro-intestinal bleeding in adults, gastro-intestinal discomfort in adults, gastro-intestinal disturbances in adults, gastro-intestinal ulceration in adults, haematuria in adults, headache in adults, hearing disturbances in adults, hypersensitivity reactions in adults, insomnia in adults, nausea in adults, nervousness in adults, photosensitivity in adults, raised blood pressure in adults, rashes in adults, renal failure (especially in patients with pre-existing renal impairment) in adults, tinnitus in adults, vertigo in adults, photosensitivity in adults, rash (discontinue use if develops) in adults,
              </p>
        
            <section class="advice">
                <h3>Serious side-effects</h3>
              <p>For information about cardiovascular and gastro-intestinal side-effects, and a possible exacerbation of symptoms in asthma, see <xref format="dita" href="#PHP78612" type="bookmark" namespace="/treatment-summaries/non-steroidal-anti-inflammatory-drugs">Non-steroidal anti-inflammatory drugs</xref>.</p>
            </section>
            <section class="advice">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use in adults</h3>
              <p>Topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported).</p>
            </section>
        
            <section class="overdosageInformation">
              <p>Overdosage with ibuprofen may cause nausea, vomiting, epigastric pain, and tinnitus, but more serious toxicity is very uncommon. <xref format="dita" href="#PHP182" type="drug" namespace="/drugs/charcoal-activated">Charcoal, activated</xref> followed by symptomatic measures are indicated if more than 100&#8239;mg/kg has been ingested within the preceding hour.</p><p>For details on the management of poisoning, see <xref format="dita" href="#PHP78558" type="bookmark" namespace="/treatment-summaries/emergency-treatment-of-poisoning">Emergency treatment of poisoning</xref>.</p>
            </section>
      </section>

      <section class="tab-pane" id="directionsForAdministration">
        <h2>Directions for administration</h2>

            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</h3>
              <p>For <i>slow intravenous injection</i>, give over 15 minutes, preferably undiluted. May be diluted with Glucose 5% <i>or</i> Sodium Chloride 0.9%.</p>
            </section>
            <section class="directionsForAdministration">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use in adults</h3>
              <p>For topical preparations, apply with gentle massage only.</p>
            </section>
      </section>

      <section class="tab-pane" id="patientAndCarerAdvice">
        <h2>Advice for patients and carers</h2>

            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use in adults</h3>
              <p>For topical preparations, patients and their carers should be advised to wash hands immediately after use.</p>
            </section>
            <section class="generalPatientAdvice">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use in adults</h3>
                <p class="title">Photosensitivity</p>
              <p>For topical preparations, patients or their carers should be advised against excessive exposure to sunlight of area treated in order to avoid possibility of photosensitivity.</p>
            </section>
            <section class="patientResources">
              <h3 class="specificity">In children</h3>
                <p class="title">Medicines for Children leaflet: Ibuprofen for pain and inflammation</p>
              <p>
            <xref format="html" href="http://www.medicinesforchildren.org.uk/ibuprofen-for-pain-and-inflammation">www.medicinesforchildren.org.uk/ibuprofen-for-pain-and-inflammation</xref>
            </p>
            </section>
      </section>



      <section class="tab-pane" id="cautions">
        <h2>Cautions regarding administration</h2>

        <ul>
          <li>
              <strong>With intravenous use:</strong>
            may mask symptoms of infection in neonates
          </li>
          <li>
              <strong>With oral use:</strong>
            cardiac impairment (NSAIDs may impair renal function) in children
          </li>
          <li>
              <strong>With oral use:</strong>
            cerebrovascular disease in children
          </li>
          <li>
              <strong>With oral use:</strong>
            coagulation defects in children
          </li>
          <li>
              <strong>With oral use:</strong>
            connective-tissue disorders in children
          </li>
          <li>
              <strong>With oral use:</strong>
            Crohn&#8217;s disease (may be exacerbated) in children
          </li>
          <li>
              <strong>With oral use:</strong>
            heart failure in children
          </li>
          <li>
              <strong>With oral use:</strong>
            ischaemic heart disease in children
          </li>
          <li>
              <strong>With oral use:</strong>
            peripheral arterial disease in children
          </li>
          <li>
              <strong>With oral use:</strong>
            risk factors for cardiovascular events in children
          </li>
          <li>
              <strong>With oral use:</strong>
            ulcerative colitis (may be exacerbated) in children
          </li>
          <li>
              <strong>With oral use:</strong>
            uncontrolled hypertension in children
          </li>
          <li>
              <strong>With systemic use:</strong>
            allergic disorders in adults
          </li>
          <li>
              <strong>With systemic use:</strong>
            cardiac impairment (NSAIDs may impair renal function) in adults
          </li>
          <li>
              <strong>With systemic use:</strong>
            cerebrovascular disease in adults
          </li>
          <li>
              <strong>With systemic use:</strong>
            coagulation defects in adults
          </li>
          <li>
              <strong>With systemic use:</strong>
            connective-tissue disorders in adults
          </li>
          <li>
              <strong>With systemic use:</strong>
            Crohn&#8217;s disease (may be exacerbated) in adults
          </li>
          <li>
              <strong>With systemic use:</strong>
            elderly (risk of serious side-effects and fatalities) in adults
          </li>
          <li>
              <strong>With systemic use:</strong>
            heart failure in adults
          </li>
          <li>
              <strong>With systemic use:</strong>
            ischaemic heart disease in adults
          </li>
          <li>
              <strong>With systemic use:</strong>
            peripheral arterial disease in adults
          </li>
          <li>
              <strong>With systemic use:</strong>
            risk factors for cardiovascular events in adults
          </li>
          <li>
              <strong>With systemic use:</strong>
            ulcerative colitis (may be exacerbated) in adults
          </li>
          <li>
              <strong>With systemic use:</strong>
            uncontrolled hypertension in adults
          </li>
          <li>
              <strong>With topical use:</strong>
            avoid contact with eyes in adults
          </li>
          <li>
              <strong>With topical use:</strong>
            avoid contact with inflamed or broken skin in adults
          </li>
          <li>
              <strong>With topical use:</strong>
            avoid contact with mucous membranes in adults
          </li>
          <li>
              <strong>With topical use:</strong>
            not for use with occlusive dressings in adults
          </li>
          <li>
              <strong>With topical use:</strong>
            topical application of large amounts can result in systemic effects, including hypersensitivity and asthma (renal disease has also been reported) in adults
          </li>
        </ul>
        <ul>
          <li>
            <p>A small increase in cardiovascular risk, similar to the risk associated with cyclo-oxygenase-2 inhibitors and diclofenac, has been reported with high-dose ibuprofen (&#8805; 2.4&#8239;g daily); use should be avoided in patients with established ischaemic heart disease, peripheral arterial disease, cerebrovascular disease, congestive heart failure (New York Heart Association classification II-III), and uncontrolled hypertension.</p>
          </li>
        </ul>
      </section>

      <section class="tab-pane" id="conceptionAndContraception">
        <h2>Advice regarding conception and contraception</h2>

            <section class="generalInformation">
              <h3 class="specificity">With <ph outputclass="route">systemic</ph> use in adults</h3>
              <p>Caution&#8212;long-term use of some NSAIDs is associated with reduced female fertility, which is reversible on stopping treatment.</p>
            </section>
      </section>

      <section class="tab-pane" id="monitoringRequirements">
        <h2>Monitoring requirements</h2>

        
          <h3>Patient parameters</h3>
        
            <section class="patientParameters">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</h3>
              <p>Monitor for bleeding.</p><p>Monitor gastro-intestinal function.</p>
            </section>
      </section>

      <section class="tab-pane" id="unlicensedUse">
        <h2>Unlicensed use</h2>

            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">intravenous</ph> use in neonates</h3>
              <p>Orphan licence for the injection for closure of ductus arteriosus in premature neonates less than 34 weeks corrected gestational age.</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>Not licensed for use in children under 3 months or body-weight under 5&#8239;kg.</p>
            </section>
            <section class="unlicensedUse">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use in children</h3>
              <p>Maximum dose for systemic juvenile idiopathic arthritis is unlicensed.</p>
            </section>
      </section>

      <section class="tab-pane" id="prescribingAndDispensingInformation">
        <h2>Information regarding prescribing and dispensing</h2>

            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Flavours of syrup may include orange.</p>
            </section>
            <section class="prescribingAndDispensingInformation">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use in children</h3>
              <p>Caution&#8212;topical preparations not generally suitable for children.</p>
            </section>
      </section>






      <section class="tab-pane" id="professionSpecificInformation">
        <h2>Profession specific information</h2>

          <h3>Dental practitioners</h3>
        
            <section class="dentalPractitionersFormulary">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Ibuprofen Oral Suspension Sugar-free may be prescribed.</p><p>Ibuprofen Tablets may be prescribed.</p>
            </section>
      </section>

      <section class="tab-pane" id="exceptionsToLegalCategory">
        <h2>Exceptions to legal category</h2>

            <section class="exceptionsToLegalCategory">
              <h3 class="specificity">With <ph outputclass="route">topical</ph> use in adults</h3>
              <p>Smaller pack sizes of gel preparations may be available on sale to the public.</p>
            </section>
            <section class="exceptionsToLegalCategory">
              <h3 class="specificity">With <ph outputclass="route">oral</ph> use</h3>
              <p>Oral preparations can be sold to the public in certain circumstances.</p>
            </section>
      </section>

      <section class="tab-pane" id="allergyAndCrossSensitivity">
        <h2>Advice regarding allergies and cross sensitivities</h2>

            <section class="contraindications">
              <p>Contraindicated in patients with a history of hypersensitivity to aspirin or any other NSAID&#8212;which includes those in whom attacks of asthma, angioedema, urticaria or rhinitis have been precipitated by aspirin or any other NSAID.</p>
            </section>
        
      </section>

      <section class="tab-pane" id="medicinalForms">
        <h2>Prepared medicinal forms of IBUPROFEN</h2>


            <section class="licensingVariationStatement">
              <p>There can be variation in the licensing of different medicines containing the same drug.</p>
            </section>
        
          <strong>Forms available from special-order manufacturers include: </strong>
            oral suspension,

            <div id="PHP77419"><a href="../medicinalForm/PHP77419.html" data-target="#PHP77419" data-action="load">Tablet</a></div>
            <div id="PHP77372"><a href="../medicinalForm/PHP77372.html" data-target="#PHP77372" data-action="load">Orodispersible tablet</a></div>
            <div id="PHP77359"><a href="../medicinalForm/PHP77359.html" data-target="#PHP77359" data-action="load">Modified-release tablet</a></div>
            <div id="PHP77409"><a href="../medicinalForm/PHP77409.html" data-target="#PHP77409" data-action="load">Capsule</a></div>
            <div id="PHP77385"><a href="../medicinalForm/PHP77385.html" data-target="#PHP77385" data-action="load">Modified-release capsule</a></div>
            <div id="PHP77365"><a href="../medicinalForm/PHP77365.html" data-target="#PHP77365" data-action="load">Effervescent granules</a></div>
            <div id="PHP77413"><a href="../medicinalForm/PHP77413.html" data-target="#PHP77413" data-action="load">Oral suspension</a></div>
            <div id="PHP77400"><a href="../medicinalForm/PHP77400.html" data-target="#PHP77400" data-action="load">Solution for infusion</a></div>
            <div id="PHP77392"><a href="../medicinalForm/PHP77392.html" data-target="#PHP77392" data-action="load">Foam</a></div>
            <div id="PHP77344"><a href="../medicinalForm/PHP77344.html" data-target="#PHP77344" data-action="load">Gel</a></div>
            <div id="PHP77351"><a href="../medicinalForm/PHP77351.html" data-target="#PHP77351" data-action="load">Spray</a></div>
            <div id="PHP77428"><a href="../medicinalForm/PHP77428.html" data-target="#PHP77428" data-action="load">Powder</a></div>
      </section>
    </div>
  </div>

  <script src="http://mattonfoot.github.io/NICE.UI/scripts/vendor/jquery.js"></script>
  <script src="http://cdn.nice.org.uk/V3/Scripts/twitter.bootstrap.js"></script>
  <script src="/content/scripts/NICE.RemoteLoad.js"></script>
</html>
